Parenteral Manual

Cloxacillin sodium

Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
ORBENIN®, TEGOPEN®, BACTOPEN®
Classification: 
Antibiotic
Original Date: 
August 2005
Revised Date: 
August 2017
Indications: 
  • Semi-synthetic penicillin for infections due to susceptible beta-lactamase producing staphylococci
Reconstitution and Stability: 

VIAL SIZE

STERILE WATER for INJECTION REQUIRED

FINAL CONCENTRATION

500 mg

4.9 mL

100 mg/mL

2,000 mg

18.7 mL

100 mg/mL

  • Reconstituted solution stable 24 hrs at room temperature or 7 days refrigerated
  • Diluted solutions stable 28 days refrigerated (2.5-40 mg/mL)
Compatibility: 

- Solutions Compatible:  dextrose, 0.9% NaCl, ringer's solution

- Additives/Above Cassette Compatible:  potassium chloride (up to 60 mmol/L)

- Y-site Compatible: potassium chloride (up to 60 mmol/L), amino acids and dextrose, morphine

- Incompatible: lipids (fat emulsion)

Administration: 

(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)

SC NO
IM YES, deep into muscle
IV Direct

Usually not given due to vein irritation

IV Intermittent Infusion YES
Usual dilution: 20 mg/mL
Infusion time: 30-60 minutes
IV Continuous Infusion YES

 

 

Dosage: 

(For neonatal dosages, refer to Neonatal IV Drug Manual.)

PEDIATRIC:     

  • Mild-Moderate Infections: 100-200 mg/kg/day IV/IM ÷ Q4 -  6H (Max 2 g/dose)
  • Severe Infections: 150-200 mg/kg/day IV/IM ÷ Q 4 - 6 H (Max 2 g/dose)
    (Maximum: 12 g/day)

ADOLESCENT/ADULT:             

  • 1 - 2 g IV/IM Q 4-6 H; up to 2 g Q 4H
Potential hazards of parenteral administration: 
  • Hypersensitivity reaction (cross-sensitivity with other penicillins or cephalosporins)
  • Skin rashes, urticaria
  • Thrombophlebitis
  • Possibility of seizures when large doses are administered in patients with renal impairment or when dose is infused too quickly
  • Rarely eosinophilia, mild leukopenia, elevated SGOT, proteinuria, elevated BUN
Notes: 
  • Monitor CBC with differential, urinalysis, serum creatinine, BUN, liver enzymes

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.